{
    "nct_id": "NCT05335811",
    "official_title": "First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging",
    "inclusion_criteria": "* Patient >/= 18 years of age.\n* Patients with histologic diagnosis of solid or liquid tumor treated by ICI with evidence of or clinical suspicion of irAE or patients with suspected inflammation.\n* Normal range standard renal and liver function tests for age:\n\neGFR >= 60 mL/min/1.73 m2\n\nAdequate liver function:\n\nBilirubin ≤ the upper limit of normal (ULN) Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ the ULN\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or lactating women: pregnant women are excluded from this study because the effects of [18F]4FN in pregnancy are not known. Urine or serum pregnancy test (female </= 60 years of age or childbearing potential) within 24 hours of the PET scan.\n* Subjects with contraindications to the use of [18F]4FN including confirmed allergy.\n* Patients with a body weight of 400 pounds or more, or a BMI which precludes their entry into the bore of the PET/CT scanner, because the hardware is not intended to support that weight.\n* Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the physician may significantly interfere with study compliance.\n* Children below the age of 18 are excluded because of the unknown but potential risk of administration of radiopharmaceuticals to minors.",
    "miscellaneous_criteria": ""
}